Glyset: Advanced Glycemic Control for Type 2 Diabetes
Glyset
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.60 | $78.00 (0%) | 🛒 Add to cart |
| 60 | $1.95 | $156.00 $117.00 (25%) | 🛒 Add to cart |
| 90 | $1.73
Best per pill | $234.00 $156.00 (33%) | 🛒 Add to cart |
Synonyms | |||
Glyset (miglitol) is an alpha-glucosidase inhibitor designed specifically for the management of type 2 diabetes mellitus. It functions by delaying the digestion of ingested carbohydrates, thereby reducing the postprandial rise in blood glucose. This oral anti-diabetic agent is indicated as an adjunct to diet and exercise to improve glycemic control in adults. It may be used as monotherapy or in combination with a sulfonylurea when hyperglycemia cannot be adequately controlled with dietary modifications, physical activity, or other agents alone. Clinical evidence supports its efficacy in lowering HbA1c and mitigating glucose spikes after meals, offering a targeted mechanism for mealtime glucose management.
Features
- Active pharmaceutical ingredient: Miglitol 25mg, 50mg, or 100mg per tablet
- Pharmacologic class: Alpha-glucosidase inhibitor
- Delays carbohydrate digestion in the small intestine
- Reduces postprandial hyperglycemia
- Available as scored, white to off-white oral tablets
- Prescription-only medication
Benefits
- Effectively lowers postprandial blood glucose excursions
- Contributes to a reduction in glycosylated hemoglobin (HbA1c) levels
- May reduce the risk of long-term diabetic complications associated with hyperglycemia
- Does not cause hypoglycemia when used as monotherapy
- Minimal systemic absorption; acts locally within the gastrointestinal tract
- Compatible with combination therapy regimens for intensified glycemic control
Common use
Glyset is commonly prescribed for the management of type 2 diabetes in adult patients. It is used when glycemic targets are not met through lifestyle interventions alone. It is particularly beneficial for individuals experiencing significant postprandial glucose elevations. The medication is often introduced when metformin is contraindicated or not tolerated, or as an add-on therapy to other oral antidiabetic drugs like sulfonylureas. It is not indicated for type 1 diabetes or diabetic ketoacidosis.
Dosage and direction
The dosage of Glyset must be individualized based on tolerance and effectiveness. The usual starting dose is 25 mg taken orally three times daily at the start (with the first bite) of each main meal. The dose may be increased after 4 to 8 weeks to 50 mg three times daily. Further titration to a maintenance dose of 100 mg three times daily may be undertaken if necessary for optimal glycemic control and if tolerated. Dosage adjustments should be made under medical supervision. Tablets should be swallowed whole with a small amount of liquid.
Precautions
Patients should be advised that Glyset may cause gastrointestinal symptoms such as flatulence, diarrhea, and abdominal pain, especially at the beginning of therapy. These effects usually diminish over time. Renal impairment requires caution; the drug is not recommended in patients with severe renal impairment (creatinine clearance <25 mL/min). It is not intended for use in patients with inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction. Periodic monitoring of hepatic and renal function is advised during long-term therapy.
Contraindications
Glyset is contraindicated in patients with known hypersensitivity to miglitol or any component of the formulation. It is also contraindicated in patients with diabetic ketoacidosis, inflammatory bowel disease, colonic ulceration, or chronic intestinal diseases associated with marked disorders of digestion or absorption. It should not be used in patients with conditions that may deteriorate as a result of increased gas formation in the intestine. Use is contraindicated in patients with severe renal impairment.
Possible side effects
The most commonly reported adverse reactions are gastrointestinal in nature, due to the local mechanism of action. These include:
- Flatulence (41.5%)
- Diarrhea (28.7%)
- Abdominal pain (11.7%)
- Nausea (6.1%) Less common side effects may include skin rash (approximately 4.3%) and transient elevations of serum transaminases. Hypoglycemia may occur when Glyset is used in combination with sulfonylureas or insulin.
Drug interactions
Since Glyset delays carbohydrate digestion, it may affect the absorption of other orally administered drugs. It may reduce the bioavailability of ranitidine and propranolol. Conversely, digestive enzymes (e.g., amylase, pancreatin) and intestinal adsorbents (e.g., charcoal) may reduce the efficacy of Glyset and should not be taken concomitantly. When used with sulfonylureas or insulin, the risk of hypoglycemia increases, potentially necessitating dose adjustment of these agents.
Missed dose
If a dose is missed, it should be omitted if it is almost time for the next scheduled dose. Do not double the dose to make up for a missed one. The medication should be taken with the first bite of each main meal for optimal efficacy. Taking it without food or long after a meal reduces its therapeutic effect.
Overdose
An overdose of Glyset is not expected to produce severe systemic symptoms due to its limited absorption. However, it may result in transient increases in flatulence, diarrhea, or abdominal discomfort. Hypoglycemia has not been observed with miglitol monotherapy overdose. In cases of suspected overdose, symptomatic and supportive measures should be instituted. Since the drug is not dialyzable, hemodialysis is not effective.
Storage
Store Glyset tablets at controlled room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep the container tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for medical professionals and patients prescribed Glyset. It is not exhaustive and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with any questions regarding a medical condition or medication. Do not disregard professional medical advice or delay seeking it based on information provided here.
Reviews
Glyset has been evaluated in multiple clinical trials and is regarded as an effective option for targeting postprandial hyperglycemia. In a 1-year multicenter study, miglitol 100 mg three times daily reduced HbA1c by an average of 0.7% compared to placebo. Patients and clinicians note its specific utility in controlling meal-related glucose spikes, though gastrointestinal side effects are a common consideration during dose titration. Long-term users report improved day-to-day glucose stability, especially when dietary carbohydrate intake is consistent.